摘要
目的 探讨MVP联合化疗方案治疗Ⅲ～Ⅳ期非小细胞肺癌近期疗效和耐受性。方法 统计分析 1 998年 5月— 2 0 0 0年 5月接受化疗的 31例Ⅲ～Ⅳ期非小细胞肺癌患者。结果 总有效率 38.7% ,主要毒副反应为骨髓抑制和胃肠道反应。结论 MVP方案治疗非小细胞肺癌疗效肯定 ,毒性可耐受 ,可以作为一线治疗方案。
Objective To investigate the short-term treatment effect and toxicity of MVP (MMC+VDS+CDDP) for non-small-cell lung cancer (NDCLC). Methods Clinical data from 31 cases of NSCLC at stage Ⅲ～Ⅳ who received chemotherapy were analyzed during May 1998 to May 2000. Results The total response rate was 38.7%, and the major toxic and side effect occurred in tolerable myelo-suppresion and gastrointestinal tract reaction. Conclusion MVP is an effective and safe chemotherapy which can be the first choice for the treatment of NSCLC patients at the stage of Ⅲ and Ⅳ.
出处
《中国煤炭工业医学杂志》
2002年第1期55-56,共2页
Chinese Journal of Coal Industry Medicine
